neutrophil elastase inhibitors (Zeneca)

N/A

Report date: 2025/06/11 20:01:15

NME

Base Information

Drug Nameneutrophil elastase inhibitors (Zeneca)

Drug Alias NameL-Prolinamide, N-[4-[[[(4-chlorophenyl)sulfonyl]amino]carbonyl]benzoyl]-L-valyl-N-[1-[[5-(aminocarbonyl)-2-benzoxazolyl]carbonyl]-2-methylpropyl]- (S)-TFMKs (Zeneca)ZR-M200355ICI-200355

ClassificationSmall molecules

Mechanisms of ActionLeukocyte elastase inhibitors

TargetsLeukocyte elastase

Therapy Area/IndicationsInflammationRespiratory Distress Syndrome, AdultRespiratory Tract Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesZeneca Group Plc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesZeneca Group Plc

Active IndicationsN/A

Inactive IndicationsInflammationRespiratory Distress Syndrome, AdultRespiratory Tract Diseases

Other Information

ATC CodeN/A